Bryan Riggsbee will join CareDx’s board of directors on March 11, 2024. CareDx, Inc., The Transplant CompanyTM, is a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. The announcement was made today.
Michael Goldberg, the chairperson of the CareDx board, expressed his pleasure in welcoming Bryan to the board. His operational experience, financial know-how, and in-depth comprehension of molecular diagnostics revenue cycle management will enable him to contribute significantly to our board.
In his prior role as Chief Financial Officer of Myriad Genetics, Riggsbee significantly influenced the company’s corporate transformation and growth plan. After working for Laboratory Corporation of America (LabCorp) for ten years, Riggsbee has proven to be a savvy financial man. Notable finance responsibilities at General Electric Company are also part of his history. He is a certified public accountant with a North Carolina license who started his work in KPMG’s audit division.
Riggsbee expressed his excitement at joining the CareDx Board, a pioneer and authority in the field of organ transplantation. “I am excited to collaborate with the leadership team of the organization to further its goal of enhancing long-term results through the provision of creative solutions throughout the whole transplant patient journey.
George Bickerstaff, who will remain a member of the Committee, is replaced by Riggsbee as Chair of the Audit and Finance Committee when he joins the Board.
With its main office located in Brisbane, California, CareDx, Inc. is a prominent provider of precision medicine solutions. Its mission is to find, create, and market high-value, clinically distinct healthcare solutions for transplant patients and their caregivers. CareDx is the premier source of genomics-based information for transplant patients, providing testing services, products, and digital healthcare solutions throughout the pre- and post-transplant patient journey.
